newsfilter
← Latest News
GlobeNewswire·

Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

  • Cardiff Oncology Inc. (NASDAQ: CRDF) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference in a virtual format on February 25-26, 2026.
  • Interim CEO Mani Mohindru, PhD, is scheduled to present on February 25, 2026, at 1:20 PM ET.
  • The company leverages PLK1 inhibition to develop novel therapies across a range of cancers.
  • Lead asset onvansertib is an oral PLK1 inhibitor currently in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer.
  • Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials.
  • Interested parties can register for the live webcast via the "Events" section of the Cardiff Oncology website.
  • A replay of the webcast will be available after the presentation concludes.